Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.

Cimadamore A, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R.

Curr Drug Metab. 2019 Feb 25. doi: 10.2174/1389200220666190225124352. [Epub ahead of print]

PMID:
30799789
2.

The Microbiome and Genitourinary Cancer: A Collaborative Review.

Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Maleki Vareki S, Pal SK, Sfanos KS.

Eur Urol. 2019 Apr;75(4):637-646. doi: 10.1016/j.eururo.2018.12.043. Epub 2019 Jan 15. Review.

PMID:
30655087
3.

The emerging role of circulating tumor cell detection in genitourinary cancer.

Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD.

J Urol. 2012 Jul;188(1):21-6. doi: 10.1016/j.juro.2012.02.2558. Epub 2012 May 12. Review.

PMID:
22578722
4.

Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.

Lin SY, Linehan JA, Wilson TG, Hoon DSB.

Eur Urol Focus. 2017 Apr;3(2-3):265-272. doi: 10.1016/j.euf.2017.03.009. Epub 2017 Mar 31. Review.

PMID:
28753876
5.

Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview.

Montironi R, Santoni M, Lopez-Beltran A, Cheng L, Moch H, Scarpelli M.

Curr Drug Targets. 2015;16(2):96-102. Review.

PMID:
25469883
6.

New advances in genitourinary cancer: evidence gathered in 2014.

Suárez C, Puente J, Gallardo E, Méndez-Vidal MJ, Climent MA, León L, Olmos D, García del Muro X, González-Billalabeitia E, Grande E, Bellmunt J, Mellado B, Maroto P, González del Alba A.

Cancer Metastasis Rev. 2015 Sep;34(3):443-64. doi: 10.1007/s10555-015-9577-x. Review.

PMID:
26227584
7.

Immunotherapy for genitourinary tumors.

Nakayama T, Kitano S.

Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1. Review.

PMID:
30710374
8.

Present and future of personalized medicine in adult genitourinary tumors.

Ciccarese C, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Conti A, Tortora G, Cascinu S, Montironi R.

Future Oncol. 2015;11(9):1381-8. doi: 10.2217/fon.15.30. Review.

PMID:
25952784
9.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

10.

Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice.

Chovanec M, Albany C, Mego M, Montironi R, Cimadamore A, Cheng L.

Front Oncol. 2018 Nov 28;8:571. doi: 10.3389/fonc.2018.00571. eCollection 2018.

11.

Pathology and molecular updates in tumors of the prostate: towards a personalized approach.

Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R.

Expert Rev Mol Diagn. 2017 Aug;17(8):781-789. doi: 10.1080/14737159.2017.1341314. Epub 2017 Jun 15. Review.

PMID:
28598696
12.

miRNA and cancer; computational and experimental approaches.

Tutar Y.

Curr Pharm Biotechnol. 2014;15(5):429.

PMID:
25189575
13.

Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases.

Sangoi AR, Karamchandani J, Lane B, Higgins JP, Rouse RV, Brooks JD, McKenney JK.

Mod Pathol. 2011 Mar;24(3):425-9. doi: 10.1038/modpathol.2010.196. Epub 2010 Nov 19.

14.

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB.

Cancer Res. 1999 Jul 1;59(13):3192-8.

15.

Positron emission tomography for prostate, bladder, and renal cancer.

Schöder H, Larson SM.

Semin Nucl Med. 2004 Oct;34(4):274-92. Review.

PMID:
15493005
16.

The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Ristau BT, O'Keefe DS, Bacich DJ.

Urol Oncol. 2014 Apr;32(3):272-9. doi: 10.1016/j.urolonc.2013.09.003. Epub 2013 Dec 8. Review.

17.

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.

Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F.

Future Oncol. 2016 Sep;12(17):1971-4. doi: 10.2217/fon-2016-0166. Epub 2016 Jun 17.

18.

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.

Sweis RF, Galsky MD.

Urol Oncol. 2016 Dec;34(12):556-565. doi: 10.1016/j.urolonc.2016.10.006. Epub 2016 Nov 9. Review.

19.

Urine detection of survivin and diagnosis of bladder cancer.

Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC.

JAMA. 2001 Jan 17;285(3):324-8.

PMID:
11176843
20.

Supplemental Content

Support Center